2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

with both etanercept and adalimumab. Usually managed with steroids and antihistamine, occasionally requiring a change of anti-TNF agent. Infliximab is associated with infusion reactions ...

All patients on anti-TNF therapy should be closely monitored for TB. Injection site reactions and infusion reactions Injection site reactions are common (20-40%) with both etanercept and adalimumab.

Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine and peripheral joints that can lead to significant disability if left untreated. Conventional treatments can be ...

Discover how resolving MRI-detected inflammation improves clinical outcomes for aptients with axial spondyloarthritis.